Summary: A new meta-analysis indicates that deliberately provoking symptoms immediately before administering repetitive transcranial magnetic stimulation (rTMS) may improve clinical outcomes for obsessive-compulsive disorder (OCD) and nicotine dependence. By combining results from many studies, researchers found that rTMS paired with targeted symptom provocation produced nearly double the effectiveness compared with rTMS without provocation, suggesting a promising strategy to enhance rTMS response.
In practice, symptom provocation involves briefly activating disorder-relevant thoughts or cues just prior to stimulation. For people with OCD, this might mean triggering obsessive thoughts—for example, touching something perceived as contaminated—right before treatment. For nicotine dependence, provocation can include imagining smoking, holding a cigarette, or smelling tobacco to elicit craving. Although the findings are not yet definitive, they point to a potentially valuable way to optimize rTMS by engaging the target brain circuits at the right moment.
Key facts
- Enhanced response: rTMS paired with symptom provocation showed nearly twice the clinical effect in pooled analyses compared with rTMS without provocation.
- Targeted activation: Provocation is intended to transiently activate the neural circuits related to obsessions or cravings immediately before stimulation.
- Need for trials: The authors call for prospective, randomized studies directly comparing rTMS with and without provocation across disorders and patient populations.
Source: Vanderbilt University
Overview
Published as a large-scale meta-analysis led by Heather Burrell Ward, MD, assistant professor of Psychiatry and Behavioral Sciences and director of Neuromodulation Research, the study synthesizes evidence on whether symptom provocation affects clinical response to rTMS. Collaborators included Simon Vandekar, PhD, and student researchers Daniel Bello and Megan Jones. This is the first meta-analysis to systematically test the hypothesis that briefly activating disorder-specific symptoms immediately before rTMS changes clinical outcomes.
The research focused on the two Food and Drug Administration–cleared rTMS indications that include symptom provocation in their protocols: OCD and nicotine dependence. The authors searched multiple medical databases and identified 600 candidate studies, 71 of which met inclusion criteria for randomized clinical trials with clinical outcome measures. The meta-analysis ultimately included data from 63 studies and nearly 3,000 participants for the pooled quantitative synthesis.
Ward explains the rationale: “There is some evidence to suggest that activating a brain circuit immediately before applying rTMS will make the rTMS more effective. However, this evidence has been from small studies and has never been analyzed in large numbers to draw definitive conclusions. We therefore performed a systematic review with meta-analysis, a study that combines results from many previous studies, to investigate the effects of symptom provocation on clinical response to rTMS for OCD and nicotine dependence.”
Main findings
Overall, symptom provocation did not uniformly produce a statistically significant improvement across every analysis. However, when outcomes were compared, rTMS with symptom provocation showed substantially greater effectiveness than rTMS without provocation. Specifically:
- For OCD, active rTMS was associated with better clinical response than sham both when provocation was used (standardized mean difference, SMD = −0.51) and when it was not used (SMD = −0.29).
- For nicotine dependence, active rTMS showed a benefit over sham when paired with provocation (SMD = −0.56) but not consistently when provocation was absent (SMD = −0.35, not statistically significant in pooled analysis).
The estimated additional benefit of provocation in subgroup analyses was modest and varied by condition, but the pattern suggests provocation may enhance the likelihood of clinical response, particularly for nicotine dependence and for some OCD protocols. The authors emphasize that heterogeneity of protocols, targets, and provocation methods across studies complicates definitive conclusions.
Ward notes that symptom provocation may not be appropriate for every population or disorder. For example, some evidence suggests people with schizophrenia may not show the same cue-induced craving for cigarettes, which could limit the value of provocation in that subgroup. She is principal investigator on a clinical trial comparing rTMS interventions for nicotine use in people with and without schizophrenia, which will help clarify these questions.
Implications and next steps
This meta-analysis supports the hypothesis that activating disorder-relevant brain circuits immediately before rTMS can improve treatment response. However, the authors stress that randomized, prospective trials that directly compare rTMS with and without symptom provocation are critical to establish causality. Future research should test provocation across additional disorders, substance use conditions, and rTMS targets to determine which circuits require pre-activation for optimal modulation.
“As a psychiatrist who administers rTMS in clinical and research settings, I want to know exactly what I need to do to make rTMS as effective as possible for my patients,” Ward said. “There is so much left for us to learn about ways to optimize rTMS treatment, and Vanderbilt is a leader in that field.”
About this rTMS brain stimulation research news
Author: Craig Boerner
Source: Vanderbilt University
Contact: Craig Boerner – Vanderbilt University
Image: The image is credited to Neuroscience News
Original Research: Closed access. “Symptom Provocation and Clinical Response to Transcranial Magnetic Stimulation” by Heather Burrell Ward et al., JAMA Psychiatry
Abstract
Symptom Provocation and Clinical Response to Transcranial Magnetic Stimulation
Importance: Transcranial magnetic stimulation (TMS) is a noninvasive brain modulation technique used for major depressive disorder, obsessive-compulsive disorder (OCD), and nicotine dependence. TMS effects are state dependent, raising the question of whether activating relevant brain states before stimulation affects clinical outcomes.
Objective: To quantify the association between symptom provocation and clinical response to TMS for OCD and nicotine dependence, the two FDA-cleared TMS indications that incorporate symptom provocation.
Data sources: PubMed, CINAHL, Embase, PsycInfo through August 30, 2024.
Study selection: Randomized clinical trials of TMS for OCD or nicotine dependence reporting clinical outcomes. Of approximately 600 identified studies, 71 met inclusion criteria and were examined; 63 studies (2998 participants) contributed to the pooled meta-analysis.
Data extraction and synthesis: Independent extraction by two reviewers with cross-checking by a third. Standardized mean differences (Hedges g) were estimated and synthesized using a three-level random-effects meta-analysis. Study data were analyzed from August 2023 to March 2025.
Main outcomes and measures: Clinical response measures for OCD symptoms and cigarette use outcomes.
Results: The pooled sample included 3246 participants (mean age 37.8 years; mean percentage female 44.1%). For OCD, active TMS outperformed sham both with provocation (SMD = −0.51) and without provocation (SMD = −0.29). For nicotine use, active TMS outperformed sham when paired with provocation (SMD = −0.56) but not consistently without provocation (SMD = −0.35). Estimated added effects of provocation were modest and variable across conditions.
Conclusions and relevance: This systematic review and meta-analysis suggests symptom provocation may enhance clinical response to TMS for OCD and nicotine dependence. Well-designed randomized trials directly comparing TMS with and without provocation are needed to establish a causal effect and to inform clinical protocols.